Bioventus Inc. Files 8-K on Security Holder Matters
Ticker: BVS · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1665988
Sentiment: neutral
Topics: corporate-governance, amendment, shareholder-rights
Related Tickers: BIOV
TL;DR
Bioventus filed an 8-K detailing changes to security holder rights and corporate governance.
AI Summary
Bioventus Inc. filed an 8-K on June 17, 2024, reporting events that occurred on June 11, 2024. The filing indicates material modifications to security holder rights, amendments to articles of incorporation or bylaws, and the submission of matters to a vote of security holders. It also includes financial statements and exhibits.
Why It Matters
This filing signals potential changes in Bioventus Inc.'s corporate structure or governance that could affect shareholder rights and the company's operational framework.
Risk Assessment
Risk Level: medium — Filings related to material modifications of security holder rights and amendments to governing documents can indicate significant corporate events that may impact stock value.
Key Players & Entities
- Bioventus Inc. (company) — Registrant
- June 11, 2024 (date) — Earliest event reported
- June 17, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 4721 Emperor Boulevard, Suite 100 Durham, North Carolina 27703 (address) — Principal executive offices
FAQ
What specific material modifications were made to the rights of Bioventus Inc. security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not provided in the summary information.
Were there any amendments to Bioventus Inc.'s Articles of Incorporation or Bylaws?
Yes, the filing explicitly states 'Amendments to Articles of Incorporation or Bylaws' as an item of information.
Were any matters submitted to a vote of Bioventus Inc. security holders?
Yes, the filing lists 'Submission of Matters to a Vote of Security Holders' as an item of information.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 11, 2024.
What is the principal executive office address for Bioventus Inc.?
The principal executive office address is 4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703.
Filing Stats: 1,052 words · 4 min read · ~4 pages · Grade level 11.9 · Accepted 2024-06-17 16:53:30
Key Financial Figures
- $0.001 — which registered Class A common Stock, $0.001 par value per share BVS The Nasdaq
Filing Documents
- d775079d8k.htm (8-K) — 35KB
- d775079dex31.htm (EX-3.1) — 9KB
- d775079dex32.htm (EX-3.2) — 167KB
- 0001193125-24-162669.txt ( ) — 379KB
- bvs-20240611.xsd (EX-101.SCH) — 3KB
- bvs-20240611_lab.xml (EX-101.LAB) — 19KB
- bvs-20240611_pre.xml (EX-101.PRE) — 12KB
- d775079d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Form of Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bioventus Inc. 3.2 Second Amended and Restated Bylaws of Bioventus Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOVENTUS INC. Date: June 17, 2024 By: /s/ Anthony D'Adamio Anthony D'Adamio Senior Vice President and General Counsel